Fig. 1
Combining Vitamin C (VC) and PLX4032 synergistic inhibited the proliferation of BRAFMT thyroid cancer cells. a MTT assay was employed to evaluate cell viability after treating with indicating doses of VC and PLX4032 for 2–6 days. b Cell proliferation was evaluated with EdU assay after treating with indicating doses of VC and PLX4032 for 24 h. c colony formation assay was used to evaluate the proliferation inhibitory effect of combining therapy. d Analysis of the dose-effect relationship for PLX4032 (3-48 μM) and VC (0.1–2 mM) for the proliferative effect after 72 h of exposure in thyroid cancer cells, according to the Chou-Talalay dose-effect method. The combination index (CI) values were calculated: CI < 1, CI = 1, and CI > 1 represent synergism, additivity, and antagonism of these 2 agents, respectively. The “red arrow” represented the combination of VC (0.25 mM) and PLX4032 (6 μM). Data were presented as mean ± SD. ns, not significant; */^/#, P < 0.05; **/^^/##, P < 0.01; ***/^^^/###, P < 0.001. */ns: compared with control group; ^: compared with VC group; #: compared with PLX4032 group